Skip to main content

Table 2 Demographic information, disease history and vital signs in the baseline in three different groups in the ITT population

From: The efficacy of corticosteroids therapy in patients with moderate to severe SARS-CoV-2 infection: a multicenter, randomized, open-label trial

 

Steroid + Azithromycin

Azithromycin

Lopinavir/Ritonavir

Total

P-value

Age—mean (SD)*

58.2 (17.2)

57.6 (15.6)

58.4 (16.0)

58.1 (16.3)

0.889

Sex (Male)—no. (%)

57 (49.1)

55 (50.0)

61 (55.5)

173 (51.5)

0.307

BMI—mean (SD)

28.8 (4.7)

29.4 (5.6)

27.7 (5.8)

28.6 (5.4)

0.068

Smoking—no. (%)

     

 Never-smoker

38 (82.6)

36 (70.6)

32 (72.7)

106 (75.2)

0.625

 Current smoker

2 (4.4)

6 (11.8)

5 (11.4)

13 (9.2)

 Ex-smoker

6 (13.0)

9 (17.7)

7 (15.9)

22 (15.6)

 Total

46 (100.0)

51 (100.0)

44 (100.0)

141 (100.0)

Comorbidities—no. (%)

     

 Hypertension

23 (19.8)

30 (27.3)

30 (27.3)

83 (24.7)

0.638

 Diabetes

13 (11.2)

14 (12.7)

14 (12.7)

41 (12.2)

0.964

 Chronic heart disease

7 (6.0)

15 (13.6)

8 (7.3)

30 (8.9)

0.122

 Chronic lung disease, not asthma

4 (3.5)

6 (5.5)

5 (4.6)

15 (4.5)

0.824

 Chronic Kidny Disease

1 (0.9)

1 (0.9)

2 (1.8)

4 (1.2)

0.794

 Mild liver disease

2 (1.7)

1 (0.9)

1 (0.9)

4 (1.2)

0.125

 Rheumatologic disease

0 (0.0)

1 (0.9)

0 (0.0)

1 (0.3)

0.367

 Chronic neurologic disease

5 (4.3)

2 (1.8)

4 (3.6)

11 (3.3)

0.502

Vital signs on admission—no. (%)

     

 Fever °C—mean (SD)

37.15 (0.69)

37.20 ((0.71)

37.17 (0.69)

37.18 (0.70)

0.884

 Heart rate—mean (SD)

87.45 (14.96)

89.61 (15.23)

87.33 (14.48)

88.11 (14.87)

0.491

 Respiratory rate—median (IQR)

18 (18–20)

19 (18–22)

19 (18–22)

18 (18–21)

0.704

 O2 Saturation %—median (IQR)

90 (88–92)

90 (87–92)

90 (87–92)

90 (88–92)

0.617

 Systolic BP mmHg—mean (SD)

121.84 (16.8)

124.14 (15.4)

123.78 (15.9)

122.91 (16.0)

0.594

 Diastolic BP mmHg—mean (SD)

76.6 (10.1)

77.97 (9.9)

76.32 (9.7)

76.95 (9.9)

0.411